Strides Pharma
As of the edition of 20 October 2026, Strides Pharma runs 4 drugs, 4 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Methotrexate | none listed | 2 |
| Baclofen | none listed | 1 |
| Nystatin | none listed | 0 |
| Zafirlukast | none listed | 0 |
A route B row is one company at one target.